Molecular biology

Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards

Retrieved on: 
Wednesday, January 24, 2024

TARRYTOWN, N.Y. and WASHINGTON, D.C., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists in this year’s Regeneron Science Talent Search , the nation’s oldest and most prestigious science and math competition for high school seniors.

Key Points: 
  • TARRYTOWN, N.Y. and WASHINGTON, D.C., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists in this year’s Regeneron Science Talent Search , the nation’s oldest and most prestigious science and math competition for high school seniors.
  • "We applaud this dynamic group of Regeneron Science Talent Search finalists on their impressive achievement,” said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News.
  • The top 10 Regeneron Science Talent Search 2024 winners will be announced during an awards ceremony on March 12, streamed live from Washington D.C.
  • In total, more than $3 million in awards will be distributed throughout the Regeneron Science Talent Search.

Award-Winning Biotech Training Program to Begin Recruitment with New Employer Partner in Life Sciences

Retrieved on: 
Wednesday, January 17, 2024

This workforce development training will support the talent needs of the rapidly growing cell and gene therapy manufacturing organization.

Key Points: 
  • This workforce development training will support the talent needs of the rapidly growing cell and gene therapy manufacturing organization.
  • "Our partnership with VintaBio marks an exciting era of Life Science development in Philadelphia.
  • “Where other companies at a similar stage may focus on degreed talent, VintaBio is widening its talent pool to include candidates who complete our training program.
  • Hiring local talent is advantageous at every stage of a company life cycle and we applaud VintaBio for recognizing this and taking action."

Sensorion Appoints Dr. Federico Mingozzi as Non-Executive Director to the Board of Directors

Retrieved on: 
Thursday, January 25, 2024

Dr. Federico Mingozzi previously worked at Spark Therapeutics, where he served as Chief Science and Technology Officer.

Key Points: 
  • Dr. Federico Mingozzi previously worked at Spark Therapeutics, where he served as Chief Science and Technology Officer.
  • Federico brings over 25 years of experience in gene therapy, immunology, as well as biochemistry and molecular biology in academia and industry.
  • Federico has participated in numerous clinical trials targeting metabolic and neuromuscular diseases, hereditary blindness, and coagulation disorders.
  • Khalil Barrage, ad interim Chair of Sensorion's Board of Directors, said: "We are delighted to welcome Federico Mingozzi as new director.

Synnovation Therapeutics Launches with $102 Million to Advance Clinical-Stage Pipeline of Precision Therapies Targeting Highly Validated Disease Pathways

Retrieved on: 
Wednesday, January 24, 2024

Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, launched today with a $102 million Series A.

Key Points: 
  • Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, launched today with a $102 million Series A.
  • Synnovation was founded by a world-class medicinal chemistry team with a track record of developing best-in-class therapeutics.
  • Proceeds will fund the advancement of the company’s clinical and preclinical pipeline, including SNV1521 and SNV4818, as well as additional programs.
  • The company’s lead program, SNV1521, is a potentially best-in-class, potent, highly selective and CNS penetrant PARP1 inhibitor.

Polymerase Chain Reaction (PCR) Technologies and Global Markets 2023-2028 - New Research Signals Robust Advancements and Expanding Applications in Molecular Diagnostics - ResearchAndMarkets.com

Retrieved on: 
Friday, January 19, 2024

The "Polymerase Chain Reaction (PCR) Technologies and Global Markets 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Polymerase Chain Reaction (PCR) Technologies and Global Markets 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • From diagnostics, research, and agriculture to forensics and environmental science, PCR techniques are an essential element in the arsenal of today's scientists.
  • Although the fundamental concept of PCR has remained unchanged over the years, novel PCR methods/protocols have continued to advance.
  • With the recent inclination toward genomic and biomarker research and development, demands for advanced PCR technologies to study nucleic acid samples in greater detail have increased significantly.

Allosteric Bioscience, Inc. Signs Sponsored Research Agreement with Dr. Susan Michaelis at Johns Hopkins University for Aging/Longevity-Related Work

Retrieved on: 
Wednesday, January 17, 2024

Allosteric Bioscience, Inc. (ABI) has signed a Sponsored Research Agreement (SRA) with Dr. Susan Michaelis at Johns Hopkins University for analysis of chemical leads for modulation (increase or decrease) of key protein targets for Optimizing Aging and Longevity.

Key Points: 
  • Allosteric Bioscience, Inc. (ABI) has signed a Sponsored Research Agreement (SRA) with Dr. Susan Michaelis at Johns Hopkins University for analysis of chemical leads for modulation (increase or decrease) of key protein targets for Optimizing Aging and Longevity.
  • At Johns Hopkins University Dr. Susan Michaelis will manage the analysis.
  • Dr. Michaelis is a leader in aging research and is a Professor in Cell Biology at Johns Hopkins University, School of Medicine.
  • Participation by Dr. Susan Michaelis in the SRA does not constitute or imply endorsement of Allosteric Bioscience, Inc. (Company) by Johns Hopkins University.

Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards

Retrieved on: 
Wednesday, January 24, 2024

TARRYTOWN, N.Y. and WASHINGTON, Jan. 24, 2024 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists in this year's Regeneron Science Talent Search, the nation's oldest and most prestigious science and math competition for high school seniors.

Key Points: 
  • Regeneron Science Talent Search Showcases Exceptional Young Leaders with Innovative Ideas in Science, Technology, Engineering and Math (STEM)
    TARRYTOWN, N.Y. and WASHINGTON, Jan. 24, 2024 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists in this year's Regeneron Science Talent Search , the nation's oldest and most prestigious science and math competition for high school seniors.
  • "We applaud this dynamic group of Regeneron Science Talent Search finalists on their impressive achievement," said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News.
  • The top 10 Regeneron Science Talent Search 2024 winners will be announced during an awards ceremony on March 12, streamed live from Washington D.C.
  • In total, more than $3 million in awards will be distributed throughout the Regeneron Science Talent Search.

AtlasXomics and EpiCypher announce partnership to commercialize spatial epigenomics assays

Retrieved on: 
Tuesday, January 23, 2024

NEW HAVEN, Conn. and RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2024 /PRNewswire/ -- AtlasXomics and EpiCypher announce their partnership to develop CUT&Tag kits and assay services for spatial epigenomics applications.

Key Points: 
  • NEW HAVEN, Conn. and RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2024 /PRNewswire/ -- AtlasXomics and EpiCypher announce their partnership to develop CUT&Tag kits and assay services for spatial epigenomics applications.
  • The application of ultra-sensitive chromatin mapping assays, such as CUT&Tag, to spatial techniques is critical to the study of biological mechanisms in development and disease.
  • AtlasXomics has commercialized DBiT-seq for spatial ATAC-seq assays to map chromatin accessibility and is partnering with EpiCypher to introduce spatial CUT&Tag for profiling chromatin proteins, including histone PTMs and transcription factors.
  • EpiCypher holds key rights to CUT&Tag technology and a proprietary nucleosome-based approach to develop ultra-efficient antibodies for spatial and single cell CUT&Tag assays.

Hyris Fulfils Its Integration Into Ulisse Biomed to Give Birth to a New International Group Ready to Make Its Mark in the Global Biotech Market

Retrieved on: 
Monday, January 15, 2024

The new group, strong of flawless interoperability between its leading technologies, aims to become a new benchmark of innovation in the national and international biotech market.

Key Points: 
  • The new group, strong of flawless interoperability between its leading technologies, aims to become a new benchmark of innovation in the national and international biotech market.
  • By joining forces, we will enhance our product offering, combining our experience and development capabilities with Hyris' unique mix of competencies.
  • Stefano Lo Priore, founder of Hyris and former CEO and recently appointed Chairman of UBM Group, agrees: "We are proud of this integration between Ulisse Biomed and Hyris.
  • We are ready for the challenges that await us, strong of the competencies that the two companies will be able to pool together."

Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer

Retrieved on: 
Tuesday, January 16, 2024

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced the appointment of Joanne Quan, MD as Chief Medical Officer.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced the appointment of Joanne Quan, MD as Chief Medical Officer.
  • Dr. Quan was most recently Chief Medical Officer at Nuvig Therapeutics.
  • In tandem with Dr. Quan’s appointment, Mirum announced the promotion of Peter Radovich to President and Chief Operating Officer.
  • I’m thrilled that she is joining at such an exciting time for Mirum, strengthening our team and leadership in rare disease,” said Chris Peetz, Chief Executive Officer at Mirum.